Asian markets traded higher on Tuesday as investors await clarity on US President Donald Trump's policies.

The stock markets in the United States were closed on Monday, 20 January, on account of Martin Luther King Jr. Day holiday.

Here's a table showing how US stocks performed on Friday:

Data Source: Equitymaster

At present, the BSE Sensex is trading 124 points lower and NSE Nifty is trading 12 points higher.

Wipro, Tata Motors, BPCL are among the top gainers today.

NTPC, ONGC, and Trent hand are among the top losers today.

The BSE Midcap index is trading 0.3% lower and the BSE Smallcap index is trading marginally higher.

Sectoral indices are trading mixed today with stocks in the metal sector and the healthcare sector witnessing buying. Meanwhile, stocks inthe  realty sector and power sector witnessing selling pressure.

The rupee is trading at Rs 86.4 against the US dollar.
 

Dixon Technologies Q3 Results

Dixon Technologies, a leading electronics contract manufacturer, reported a robust 77.5% year-on-year increase in its consolidated net profit (attributable to the company's owners) for Q3FY25, reaching Rs 1.7 bn.

This is a significant rise from the Rs 0.9 bn reported in the corresponding quarter of the previous fiscal. However, on a sequential basis, the consolidated net profit saw a decline of 56%.

On Monday, Dixon Technologies' shares closed at Rs 17,554.45 apiece on the BSE, marking a 1.87% increase.

The company's consolidated revenue from operations surged by nearly 117% year-on-year to Rs 104.5 bn for the quarter ended December, compared to Rs 48.2 bn in Q3FY24.

Sequentially, however, the revenue dipped by 9.4%.

In contrast, the Consumer Electronics & Appliances division faced challenges, with revenue dropping 32% year-on-year and declining by over 50% from the September quarter, settling at ?633 crore.

The operating profit for this division also decreased, falling 31% year-on-year and 58% sequentially to Rs 220 m.

Notably, the Consumer Electronics & Appliances segment, which contributed 19% to Dixon's overall revenue in the same quarter last year, accounted for only 6% of the revenue in Q3FY25.

Here's how Dixon's stock price has moved in the past 1 year-

With such a rally, Dixon stands among Top 5 Fastest Growing Semiconductor Stocks to Watch Out for in 2025.
 

MCX Q3 Revenue Jumps 57%

Leading commodity exchange Multi Commodity Exchange of India Ltd (MCX) on Monday (20 January) reported a net profit of Rs 1.6 bn for the third quarter that ended 31 December 2024.

In the corresponding quarter of the previous fiscal, Multi Commodity Exchange of India posted a net loss of Rs 54 m.

The company's revenue from operations jumped 57.4% to Rs 3 bn against Rs 1.9 bn in the year-ago quarter.

At the operating level, EBITDA was at Rs 1.9 bn in the third quarter of this fiscal over Rs 0.2 bn loss in Q3 FY24.

The EBITDA margin stood at 64% in the reporting quarter. EBITDA is earnings before interest, tax, depreciation, and amortisation.
 

Venus Remedies Secures European Certification Renewal

Pharma major Venus Remedies Ltd on Monday (20 January) successfully renewed its European Good Manufacturing Practices (GMP) certification from Infarmed, Portugal's national authority of medicines and health products.

The certification covers the company's manufacturing facility for cephalosporin, carbapenem, and lyophilized injectable oncology formulations, reaffirming its commitment to delivering world-class pharmaceutical products to the European market.

Having initially received EU GMP certification in 2007, Venus Remedies has maintained a strong foothold in Europe for over 15 years.

The company is among the leading exporters of meropenem outside India and holds multiple marketing authorisations across the region.
 

Cipla Receives USFDA Observation

Pharma major Cipla Ltd on Monday (20 January) announced that the United States Food and Drug Administration (FDA) conducted an inspection of its wholly-owned subsidiary, Medispray Laboratories Private Ltd, located in Kundaim, Goa, from 14-20 January 2025.

Following the inspection, the facility received one observation in Form 483.

Cipla stated its commitment to working closely with the FDA to address the observation comprehensively within the stipulated timeline.

Form 483 is a list of observations made during the inspection and is issued by the FDA inspectors following the completion of the inspection.

The inspector will communicate and explain these observations to the supplier during the closing conference.

However, Form 483 does not represent a final FDA determination regarding the facility's GMP compliance.

After Form 483 is issued, the company is given 15 days' time to submit its response to the FDA explaining what steps the company will take to resolve the observations made by the US regulator.

More By This Author: